Refining biomarker evaluation in ASD

Refining biomarker evaluation in ASD

This commentary reflects on reasonable biomarker expectations in ASD by addressing three key questions: What is a biomarker? What is required for a biomarker in ASD? How can biomarkers be useful in ASD? In addressing these queries, a path forward emerges based on clear definition of the objective fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European neuropsychopharmacology 2021-07, Vol.48, p.34-36
1. Verfasser: McPartland, James C.
Format: Artikel
Sprache:eng
Schlagworte:
Autism spectrum disorder
Autism Spectrum Disorder - diagnosis
Biomarkers
Clinical trials
Endpoints
Humans
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 36
container_issue
container_start_page 34
container_title European neuropsychopharmacology
container_volume 48
creator McPartland, James C.
description This commentary reflects on reasonable biomarker expectations in ASD by addressing three key questions: What is a biomarker? What is required for a biomarker in ASD? How can biomarkers be useful in ASD? In addressing these queries, a path forward emerges based on clear definition of the objective for any given ASD biomarker and evaluation of each biomarker relative to current best practices.
doi_str_mv 10.1016/j.euroneuro.2021.03.023
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8238819</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924977X21001784</els_id><sourcerecordid>2521498658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-31184c5dd05dabbae7c95ba28f20b72442ba1a42ea2186d319d9feb7475e78493</originalsourceid><addsrcrecordid>eNqFkEtLAzEUhYMoWh9_Qbtw4WbGvKZJNkKpTxAEH-AuZDJ3auo00WSm4L93SmvRlZt7F_eccw8fQicE5wST0fkshy4Gvxw5xZTkmOWYsi00IFKwTMgR3UYDrCjPlBCve2g_pRnGpGBM7aK9fjKuKBmg00eonXd-OixdmJv4DnEIC9N0pnXBD50fjp8uD9FObZoER-t9gF6ur54nt9n9w83dZHyfWS6KNmOESG6LqsJFZcrSgLCqKA2VNcWloJzT0hDDKRhK5KhiRFWqhlL0ZhCSK3aALla5H105h8qCb6Np9Ed0fbMvHYzTfy_evelpWGhJmZRkGXC2Dojhs4PU6rlLFprGeAhd0rSghCs5KmQvFSupjSGlCPXmDcF6yVjP9IaxXjLWmOmece88_t1y4_uB2gvGKwH0rBYOok7WgbdQuQi21VVw_z75Bh_Skkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2521498658</pqid></control><display><type>article</type><title>Refining biomarker evaluation in ASD</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>McPartland, James C.</creator><creatorcontrib>McPartland, James C.</creatorcontrib><description>This commentary reflects on reasonable biomarker expectations in ASD by addressing three key questions: What is a biomarker? What is required for a biomarker in ASD? How can biomarkers be useful in ASD? In addressing these queries, a path forward emerges based on clear definition of the objective for any given ASD biomarker and evaluation of each biomarker relative to current best practices.</description><identifier>ISSN: 0924-977X</identifier><identifier>EISSN: 1873-7862</identifier><identifier>DOI: 10.1016/j.euroneuro.2021.03.023</identifier><identifier>PMID: 33934921</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Autism spectrum disorder ; Autism Spectrum Disorder - diagnosis ; Biomarkers ; Clinical trials ; Endpoints ; Humans</subject><ispartof>European neuropsychopharmacology, 2021-07, Vol.48, p.34-36</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-31184c5dd05dabbae7c95ba28f20b72442ba1a42ea2186d319d9feb7475e78493</citedby><cites>FETCH-LOGICAL-c475t-31184c5dd05dabbae7c95ba28f20b72442ba1a42ea2186d319d9feb7475e78493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.euroneuro.2021.03.023$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33934921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McPartland, James C.</creatorcontrib><title>Refining biomarker evaluation in ASD</title><title>European neuropsychopharmacology</title><addtitle>Eur Neuropsychopharmacol</addtitle><description>This commentary reflects on reasonable biomarker expectations in ASD by addressing three key questions: What is a biomarker? What is required for a biomarker in ASD? How can biomarkers be useful in ASD? In addressing these queries, a path forward emerges based on clear definition of the objective for any given ASD biomarker and evaluation of each biomarker relative to current best practices.</description><subject>Autism spectrum disorder</subject><subject>Autism Spectrum Disorder - diagnosis</subject><subject>Biomarkers</subject><subject>Clinical trials</subject><subject>Endpoints</subject><subject>Humans</subject><issn>0924-977X</issn><issn>1873-7862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEUhYMoWh9_Qbtw4WbGvKZJNkKpTxAEH-AuZDJ3auo00WSm4L93SmvRlZt7F_eccw8fQicE5wST0fkshy4Gvxw5xZTkmOWYsi00IFKwTMgR3UYDrCjPlBCve2g_pRnGpGBM7aK9fjKuKBmg00eonXd-OixdmJv4DnEIC9N0pnXBD50fjp8uD9FObZoER-t9gF6ur54nt9n9w83dZHyfWS6KNmOESG6LqsJFZcrSgLCqKA2VNcWloJzT0hDDKRhK5KhiRFWqhlL0ZhCSK3aALla5H105h8qCb6Np9Ed0fbMvHYzTfy_evelpWGhJmZRkGXC2Dojhs4PU6rlLFprGeAhd0rSghCs5KmQvFSupjSGlCPXmDcF6yVjP9IaxXjLWmOmece88_t1y4_uB2gvGKwH0rBYOok7WgbdQuQi21VVw_z75Bh_Skkw</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>McPartland, James C.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210701</creationdate><title>Refining biomarker evaluation in ASD</title><author>McPartland, James C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-31184c5dd05dabbae7c95ba28f20b72442ba1a42ea2186d319d9feb7475e78493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Autism spectrum disorder</topic><topic>Autism Spectrum Disorder - diagnosis</topic><topic>Biomarkers</topic><topic>Clinical trials</topic><topic>Endpoints</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McPartland, James C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McPartland, James C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Refining biomarker evaluation in ASD</atitle><jtitle>European neuropsychopharmacology</jtitle><addtitle>Eur Neuropsychopharmacol</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>48</volume><spage>34</spage><epage>36</epage><pages>34-36</pages><issn>0924-977X</issn><eissn>1873-7862</eissn><abstract>This commentary reflects on reasonable biomarker expectations in ASD by addressing three key questions: What is a biomarker? What is required for a biomarker in ASD? How can biomarkers be useful in ASD? In addressing these queries, a path forward emerges based on clear definition of the objective for any given ASD biomarker and evaluation of each biomarker relative to current best practices.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33934921</pmid><doi>10.1016/j.euroneuro.2021.03.023</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0924-977X
ispartof European neuropsychopharmacology, 2021-07, Vol.48, p.34-36
issn 0924-977X
1873-7862
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8238819
source MEDLINE; Elsevier ScienceDirect Journals
subjects Autism spectrum disorder
Autism Spectrum Disorder - diagnosis
Biomarkers
Clinical trials
Endpoints
Humans
title Refining biomarker evaluation in ASD
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T03%3A57%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Refining%20biomarker%20evaluation%20in%20ASD&rft.jtitle=European%20neuropsychopharmacology&rft.au=McPartland,%20James%20C.&rft.date=2021-07-01&rft.volume=48&rft.spage=34&rft.epage=36&rft.pages=34-36&rft.issn=0924-977X&rft.eissn=1873-7862&rft_id=info:doi/10.1016/j.euroneuro.2021.03.023&rft_dat=%3Cproquest_pubme%3E2521498658%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2521498658&rft_id=info:pmid/33934921&rft_els_id=S0924977X21001784&rfr_iscdi=true